O	0	1	A
O	2	7	pilot
O	8	13	study
O	14	16	of
B-intervention	17	28	minocycline
O	29	32	for
O	33	36	the
O	37	47	prevention
O	48	50	of
B-condition	51	61	paclitaxel
I-condition	61	62	-
I-condition	62	72	associated
I-condition	73	83	neuropathy
O	83	84	:
O	85	90	ACCRU
O	91	96	study
O	97	106	RU221408I
O	106	107	.

O	108	118	Paclitaxel
O	119	121	is
O	122	132	associated
O	133	137	with
O	138	142	both
O	143	145	an
O	146	151	acute
O	152	156	pain
O	157	165	syndrome
O	166	167	(
O	167	168	P
O	168	169	-
O	169	172	APS
O	172	173	)
O	174	177	and
O	178	185	chronic
O	186	198	chemotherapy
O	198	199	-
O	199	206	induced
O	207	217	peripheral
O	218	228	neuropathy
O	229	230	(
O	230	234	CIPN
O	234	235	)
O	235	236	.

O	237	242	Given
O	243	247	that
O	248	257	extensive
O	258	264	animal
O	265	269	data
O	270	277	suggest
O	278	282	that
O	283	294	minocycline
O	295	298	may
O	299	306	prevent
O	307	319	chemotherapy
O	319	320	-
O	320	327	induced
O	328	341	neurotoxicity
O	341	342	,
O	343	346	the
O	347	354	purpose
O	355	357	of
O	358	362	this
O	363	368	pilot
O	369	374	study
O	375	378	was
O	379	381	to
O	382	393	investigate
O	394	397	the
O	398	406	efficacy
O	407	409	of
O	410	421	minocycline
O	422	425	for
O	426	429	the
O	430	440	prevention
O	441	443	of
O	444	448	CIPN
O	449	452	and
O	453	456	the
O	457	458	P
O	458	459	-
O	459	462	APS
O	462	463	.

B-eligibility	464	472	Patients
I-eligibility	473	477	with
I-eligibility	478	484	breast
I-eligibility	485	491	cancer
O	492	496	were
O	497	505	enrolled
O	506	511	prior
O	512	514	to
O	515	525	initiating
O	526	537	neoadjuvant
O	538	540	or
O	541	549	adjuvant
O	550	556	weekly
O	557	567	paclitaxel
O	568	571	for
O	572	574	12
O	575	580	weeks
O	581	584	and
O	585	589	were
O	590	600	randomized
O	601	603	to
O	604	611	receive
O	612	623	minocycline
O	624	627	200
O	628	630	mg
O	631	633	on
O	634	637	day
O	638	639	1
O	640	648	followed
O	649	651	by
O	652	655	100
O	656	658	mg
O	659	664	twice
O	665	670	daily
O	671	673	or
O	674	675	a
O	676	684	matching
B-control	685	692	placebo
O	692	693	.

O	694	702	Patients
O	703	712	completed
O	713	714	(
O	714	715	1
O	715	716	)
O	717	719	an
O	720	725	acute
O	726	730	pain
O	731	739	syndrome
O	740	753	questionnaire
O	754	759	daily
O	760	766	during
O	767	779	chemotherapy
O	780	782	to
O	783	790	measure
O	791	792	P
O	792	793	-
O	793	796	APS
O	797	800	and
O	801	802	(
O	802	803	2
O	803	804	)
O	805	808	the
O	809	814	EORTC
O	815	818	QLQ
O	818	819	-
O	819	825	CIPN20
O	826	839	questionnaire
O	840	842	at
O	843	851	baseline
O	851	852	,
O	853	858	prior
O	859	861	to
O	862	866	each
O	867	871	dose
O	872	874	of
O	875	885	paclitaxel
O	885	886	,
O	887	890	and
O	891	898	monthly
O	899	902	for
O	903	904	6
O	905	911	months
O	912	916	post
O	917	926	treatment
O	926	927	,
O	928	930	to
O	931	938	measure
O	939	943	CIPN
O	943	944	.

B-total-participants	945	950	Forty
I-total-participants	950	951	-
I-total-participants	951	956	seven
O	957	965	patients
O	966	970	were
O	971	981	randomized
O	981	982	.

O	983	988	There
O	989	993	were
O	994	996	no
O	997	1007	remarkable
O	1008	1019	differences
O	1020	1025	noted
O	1026	1033	between
O	1034	1037	the
O	1038	1049	minocycline
O	1050	1053	and
O	1054	1061	placebo
O	1062	1068	groups
O	1069	1072	for
O	1073	1076	the
O	1077	1084	overall
O	1085	1092	sensory
O	1093	1103	neuropathy
O	1104	1109	score
O	1110	1112	of
O	1113	1116	the
O	1117	1122	EORTC
O	1123	1126	QLQ
O	1126	1127	-
O	1127	1133	CIPN20
O	1134	1136	or
O	1137	1140	its
O	1141	1151	individual
O	1152	1162	components
O	1162	1163	,
O	1164	1169	which
O	1170	1178	evaluate
O	1179	1187	tingling
O	1187	1188	,
O	1189	1197	numbness
O	1198	1201	and
O	1202	1210	shooting
O	1210	1211	/
O	1211	1218	burning
O	1219	1223	pain
O	1224	1226	in
O	1227	1232	hands
O	1233	1236	and
O	1237	1241	feet
O	1241	1242	.

O	1243	1250	However
O	1250	1251	,
O	1252	1260	patients
O	1261	1267	taking
O	1268	1279	minocycline
O	1280	1283	had
O	1284	1285	a
O	1286	1297	significant
O	1298	1307	reduction
O	1308	1310	in
O	1311	1314	the
O	1315	1320	daily
B-outcome	1321	1328	average
I-outcome	1329	1333	pain
I-outcome	1334	1339	score
O	1340	1350	attributed
O	1351	1353	to
O	1354	1355	P
O	1355	1356	-
O	1356	1359	APS
O	1360	1361	(
O	1361	1362	p
O	1363	1364	=
O	1365	1366	0
O	1366	1367	.
O	1367	1369	02
O	1369	1370	)
O	1370	1371	.

O	1372	1375	Not
O	1376	1380	only
O	1381	1385	were
B-outcome	1386	1388	no
I-outcome	1389	1398	increased
I-outcome	1399	1409	toxicities
O	1410	1418	reported
O	1419	1423	with
O	1424	1435	minocycline
O	1435	1436	,
O	1437	1440	but
O	1441	1446	there
O	1447	1450	was
O	1451	1452	a
O	1453	1464	significant
O	1465	1474	reduction
O	1475	1477	in
B-outcome	1478	1485	fatigue
O	1486	1487	(
O	1487	1488	p
O	1489	1490	=
O	1491	1492	0
O	1492	1493	.
O	1493	1495	02
O	1495	1496	)
O	1496	1497	.

O	1498	1505	Results
O	1506	1508	of
O	1509	1513	this
O	1514	1519	pilot
O	1520	1525	study
O	1526	1528	do
O	1529	1532	not
O	1533	1540	support
O	1541	1544	the
O	1545	1548	use
O	1549	1551	of
O	1552	1563	minocycline
O	1564	1566	to
O	1567	1574	prevent
O	1575	1579	CIPN
O	1579	1580	,
O	1581	1584	but
O	1585	1592	suggest
O	1593	1597	that
O	1598	1600	it
O	1601	1604	may
O	1605	1611	reduce
B-outcome-Measure	1612	1613	P
I-outcome-Measure	1613	1614	-
I-outcome-Measure	1614	1617	APS
O	1618	1621	and
O	1622	1630	decrease
B-outcome-Measure	1631	1638	fatigue
O	1638	1639	;
O	1640	1647	further
O	1648	1653	study
O	1654	1656	of
O	1657	1660	the
O	1661	1667	impact
O	1668	1670	of
O	1671	1675	this
O	1676	1681	agent
O	1682	1684	on
O	1685	1690	those
O	1691	1700	endpoints
O	1701	1704	may
O	1705	1707	be
O	1708	1717	warranted
O	1717	1718	.
